Blood Tests Now Option for Colon Cancer Screening

When Adrian Ford felt mild abdominal discomfort at 31, she never imagined it would lead to a stage 4 colorectal cancer diagnosis. Active, healthy, and recently cleared in a checkup, she represents a troubling trend: colorectal cancer is climbing among young adults at an alarming rate.

But there's promising news in the fight against this disease. The American Cancer Society just updated its screening guidelines to include blood tests as an option for the first time, potentially reaching millions who have avoided traditional screening methods.

The numbers tell a serious story. Between 2013 and 2022, colorectal cancer rates among people under 50 jumped 3% each year. It's now the leading cancer killer for men under 50 in the United States. These aren't just statistics about older adults with clear risk factors. They're people like Ford: young, active, and seemingly healthy.

The new guidelines recommend that all adults 45 and older get regular screenings. While colonoscopies and stool tests remain the gold standard, blood tests now offer a third path for those who refuse or can't complete traditional screening.

"There are many people who cannot or will not undergo colonoscopy, or who are not willing to collect a stool sample," said Dr. William Dahut, chief scientific officer at the American Cancer Society. "More options may help more people get screened, detect cancer earlier and allow us to cure more patients."

The blood test option addresses a critical gap. Many people avoid screening altogether because of fear, embarrassment, or difficulty accessing colonoscopy facilities. A simple blood draw could mean the difference between early detection and a late-stage diagnosis.

The test works by detecting cancer DNA in the bloodstream. Guardant Health's Shield test is the first approved under these guidelines. While it's not as sensitive as colonoscopy for finding early polyps, it's far better than no screening at all.

The Bright Side

This expansion of screening options represents a significant shift in cancer prevention strategy. Instead of one-size-fits-all recommendations, doctors can now meet patients where they are and offer alternatives that fit their lives.

The timing matters. As colorectal cancer increasingly affects younger people without traditional risk factors, accessibility becomes crucial. A 35-year-old who experiences persistent symptoms can now pursue screening without the intimidation factor of a colonoscopy.

The guidelines emphasize informed choice. Before ordering a blood test, doctors must explain that colonoscopy remains more effective and that positive blood test results still require follow-up colonoscopy. But for the estimated millions who currently avoid all screening, this represents real progress.

The recommendations also lower the screening age to 45 for average-risk adults, acknowledging the shift toward younger diagnoses. For higher-risk individuals with family history, inflammatory bowel disease, or genetic syndromes, more intensive screening remains essential.

Ford's story underscores why these changes matter. Despite being young and healthy, she faced advanced cancer. Early detection through accessible screening could have caught her cancer when treatment options were broader and outcomes better.

The medical community stresses that symptoms require immediate attention. Bleeding, persistent abdominal pain, or bowel habit changes warrant direct colonoscopy, not blood or stool testing. But for symptom-free adults who keep postponing that colonoscopy, a blood test option removes a major barrier.

Public health experts hope the expanded options will increase overall screening rates, which currently lag behind goals. Only about two-thirds of eligible adults are up to date on colorectal cancer screening, leaving millions at risk.

As research continues into why young adult rates are rising, these new guidelines offer immediate practical help. More screening options mean more chances to catch cancer early, when it's most treatable and survival rates are highest.